A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of Subcutaneously Administered SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease
Latest Information Update: 08 Jan 2026
At a glance
- Drugs SRSD 107 (Primary)
- Indications Coronary artery disease; Peripheral arterial disorders
- Focus Therapeutic Use
- Sponsors Sirius Therapeutics
Most Recent Events
- 08 Jan 2026 New trial record